Skip to content
SPACListing
Browse
ScreenerFilingsMarketDeadlinesSponsorsBanksSectorsLearnPricingWatchlist
Liquidated

Medicus Sciences Acquisition Corp.

CIK 0001836517

Cash in trust

$92.4M

$92,386,645

Trust per share

$10.04

Redemption value

IPO

Feb 2021

$92.0M raised

Combination deadline

Not disclosed

Filings on record

57

Latest Feb 12, 2024

Overview

Medicus Sciences Acquisition Corp. is a special purpose acquisition company incorporated in Cayman Islands and registered with the SEC under CIK 0001836517. It completed its initial public offering in Feb 2021, raising $92.0M in gross proceeds. The vehicle is sponsored by Medicus Sciences through Medicus Sciences Holdings LLC. The mandate targets technology, healthcare. Deadline lapsed without a deal; trust returned to public shareholders.

we intend to focus our search for a target business operating in the medical technology sector.
The mandate, as stated in the IPO prospectus

Reading the filings

Arithmetic on what Medicus Sciences Acquisition Corp. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.

  • Trust versus the $10 unit

    The trust holds $10.04 per public share, 0.4% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.

  • Underwriting

    Maxim Group led the offering. It has been named on 31 SPAC IPOs, book-running 23 of them, and 28.6% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.

SEC filing history

Free tier: filings older than 24 hours
  • SC 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001604488-24-000047

    Feb 12, 2024

    2y ago

    Open filing
  • SC 13G/A

    FORM SC 13G/A

    Accession 0001062993-24-002516

    Feb 8, 2024

    2y ago

    Open filing
  • 15-12G

    Deregistration of securities

    Accession 0001104659-23-025886

    Feb 27, 2023

    3y ago

    Open filing
  • 25-NSE

    Notification of delisting

    Accession 0001354457-23-000099

    Feb 17, 2023

    3y ago

    Open filing
  • SC 13G/A

    SC 13G/A

    Accession 0001104659-23-021733

    Feb 14, 2023

    3y ago

    Open filing
  • SC 13G

    Beneficial ownership report (passive)

    Accession 0001076809-23-000122

    Feb 14, 2023

    3y ago

    Open filing
  • SC 13G

    Beneficial ownership report (passive)

    Accession 0001604488-23-000043

    Feb 14, 2023

    3y ago

    Open filing
  • 8-K

    Other events

    Items 8.01, 9.01 · Accession 0001104659-23-018919

    Feb 13, 2023

    3y ago

    Open filing
  • SC 13G/A

    SCHEDULE 13G/A (AMENDMENT NO. 1)

    Accession 0000899140-23-000273

    Feb 10, 2023

    3y ago

    Open filing
  • SC 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001085146-23-000337

    Jan 24, 2023

    3y ago

    Open filing
  • 8-K

    Notice of delisting or failure to satisfy a listing rule

    Item 3.01 · Accession 0001104659-23-004407

    Jan 18, 2023

    3y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001104659-22-118537

    Nov 14, 2022

    3y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001104659-22-089384

    Aug 11, 2022

    4y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001104659-22-059489

    May 12, 2022

    4y ago

    Open filing
  • 10-K

    Annual report

    Accession 0001104659-22-040275

    Mar 30, 2022

    4y ago

    Open filing
  • 8-K

    Current report

    Item 5.02 · Accession 0001104659-22-038841

    Mar 28, 2022

    4y ago

    Open filing
  • SC 13G

    Beneficial ownership report (passive)

    Accession 0001085146-22-001242

    Mar 11, 2022

    4y ago

    Open filing
  • 8-K

    Regulation FD disclosure

    Item 7.01 · Accession 0001104659-22-023798

    Feb 15, 2022

    4y ago

    Open filing
  • SC 13G

    Beneficial ownership report (passive)

    Accession 0000899140-22-000298

    Feb 14, 2022

    4y ago

    Open filing
  • SC 13G

    Beneficial ownership report (passive)

    Accession 0001104659-22-022850

    Feb 14, 2022

    4y ago

    Open filing
  • SC 13G/A

    SC 13G/A

    Accession 0001104659-22-021996

    Feb 14, 2022

    4y ago

    Open filing
  • SC 13G/A

    FORM SC 13G/A

    Accession 0001062993-22-003964

    Feb 14, 2022

    4y ago

    Open filing
  • 8-K

    Regulation FD disclosure

    Item 7.01 · Accession 0001104659-22-013066

    Feb 8, 2022

    4y ago

    Open filing
  • 10-Q/A

    10-Q/A

    Accession 0001104659-22-005991

    Jan 20, 2022

    4y ago

    Open filing
  • SC 13G

    Beneficial ownership report (passive)

    Accession 0001104659-22-004895

    Jan 18, 2022

    4y ago

    Open filing
  • 8-K

    Current report

    Item 4.02 · Accession 0001104659-21-146778

    Dec 6, 2021

    4y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001104659-21-134479

    Nov 4, 2021

    4y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001104659-21-100795

    Aug 5, 2021

    5y ago

    Open filing
  • SC 13G

    Beneficial ownership report (passive)

    Accession 0001062993-21-007086

    Aug 5, 2021

    5y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001104659-21-070794

    May 24, 2021

    5y ago

    Open filing

Medicus Sciences Acquisition Corp.: questions answered

What is Medicus Sciences Acquisition Corp.?

Medicus Sciences Acquisition Corp. is a special purpose acquisition company incorporated in Cayman Islands and registered with the SEC under CIK 0001836517. It completed its initial public offering in Feb 2021, raising $92.0M in gross proceeds. The vehicle is sponsored by Medicus Sciences through Medicus Sciences Holdings LLC. The mandate targets technology, healthcare. Deadline lapsed without a deal; trust returned to public shareholders.

How much does Medicus Sciences Acquisition Corp. hold in trust?

Approximately $92,386,645, or about $10.04 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.

When must Medicus Sciences Acquisition Corp. complete a merger?

No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.

What happens if Medicus Sciences Acquisition Corp. does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in Medicus Sciences Acquisition Corp., and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.04 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

Is the trust value the same as the share price for Medicus Sciences Acquisition Corp.?

No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.

Who sponsors Medicus Sciences Acquisition Corp., and what is their track record?

Medicus Sciences Holdings LLC is the sponsor entity, part of the Medicus Sciences franchise. This is the only vehicle we have attributed to that sponsor.

Which banks underwrote the Medicus Sciences Acquisition Corp. IPO?

Maxim Group. Syndicate membership and role are read from the prospectus cover and the underwriting section.

Is Medicus Sciences Acquisition Corp. a good investment?

That is not a question this site answers. Medicus Sciences Acquisition Corp. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this Medicus Sciences Acquisition Corp. data come from?

Filings Medicus Sciences Acquisition Corp. submitted to the SEC under CIK 0001836517: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Sep 4, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.